Plain-English translation of NCT04704323 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is the first human trial of , a new antibody designed to fight chronic lymphocytic leukemia (a blood cancer) in patients whose disease has come back or stopped responding to previous treatments. The trial has two phases: first, doctors will test increasing doses to find the safest and most effective dose, then they will treat more patients at that dose to see how well the medication works and confirm it is tolerable.
Even with newer treatments available, some patients with chronic lymphocytic leukemia do not respond to current options or their cancer comes back. This medication takes a different approach by targeting cells in specific locations where leukemia cells hide and survive, offering hope for patients who have run out of other treatment choices.
You likely qualify if…
You likely don't qualify if…
Participants will receive intravenous infusions of the new medication at a clinic or hospital. The trial is divided into two phases: in the first phase, small groups of patients will receive gradually increasing doses to find the best dose with acceptable side effects; in the second phase, a larger group will receive the recommended dose. Throughout the trial, you will have regular blood tests, imaging scans, and medical check-ups to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Spain